# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Brookline Capital analyst Kemp Dolliver initiates coverage on iBio (AMEX:IBIO) with a Buy rating and announces Price Target ...
https://patentcenter.uspto.gov/applications/17821295/ifw/docs
Chardan Capital analyst Keay Nakae maintains iBio (AMEX:IBIO) with a Buy and maintains $5 price target.
Chardan Capital analyst Keay Nakae initiates coverage on iBio (AMEX:IBIO) with a Buy rating and announces Price Target of $5.
iBio (AMEX:IBIO) reported quarterly losses of $(0.71) per share. This is a 92.55 percent increase over losses of $(9.53) per sh...
-SEC Filing
iBio surged after collaborating with AstralBio Inc. to develop antibodies for obesity & cardiometabolic conditions. Shares ...
IBIO: 119% | IBio shares are trading higher after the company collaborated with AstralBio for AI drug-powered antibodies for ob...